Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform.

Raymond S, Nicot F, Carcenac R, Lefebvre C, Jeanne N, Saune K, Delobel P, Izopet J.

J Antimicrob Chemother. 2018 Feb 12. doi: 10.1093/jac/dky003. [Epub ahead of print]


Performance comparison of next-generation sequencing platforms for determining HIV-1 coreceptor use.

Raymond S, Nicot F, Jeanne N, Delfour O, Carcenac R, Lefebvre C, Cazabat M, Sauné K, Delobel P, Izopet J.

Sci Rep. 2017 Feb 10;7:42215. doi: 10.1038/srep42215.


No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy.

Raymond S, Nicot F, Carcenac R, Jeanne N, Cazabat M, Requena M, Cuzin L, Delobel P, Izopet J; ANRS 145 MARIMUNO Study Group.

AIDS. 2016 Mar 27;30(6):965-8. doi: 10.1097/QAD.0000000000001013.


Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy.

Lhomme S, Kamar N, Nicot F, Ducos J, Bismuth M, Garrigue V, Petitjean-Lecherbonnier J, Ollivier I, Alessandri-Gradt E, Goria O, Barth H, Perrin P, Saune K, Dubois M, Carcenac R, Lefebvre C, Jeanne N, Abravanel F, Izopet J.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1608-14. doi: 10.1128/AAC.02496-15.


Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism.

Jeanne N, Saliou A, Carcenac R, Lefebvre C, Dubois M, Cazabat M, Nicot F, Loiseau C, Raymond S, Izopet J, Delobel P.

Sci Rep. 2015 Nov 20;5:16944. doi: 10.1038/srep16944.


Minority resistant HIV-1 variants and the response to first-line NNRTI therapy.

Nicot F, Sauné K, Raymond S, Jeanne N, Carcenac R, Lefebvre C, Cuzin L, Marchou B, Delobel P, Izopet J.

J Clin Virol. 2015 Jan;62:20-4. doi: 10.1016/j.jcv.2014.10.020. Epub 2014 Nov 20.


Characterization of CXCR4-using HIV-1 during primary infection by ultra-deep pyrosequencing.

Raymond S, Saliou A, Nicot F, Delobel P, Dubois M, Carcenac R, Sauné K, Marchou B, Massip P, Izopet J.

J Antimicrob Chemother. 2013 Dec;68(12):2875-81. doi: 10.1093/jac/dkt290. Epub 2013 Jul 18.


Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice.

Benkhelifa-Ziyyat S, Besse A, Roda M, Duque S, Astord S, Carcenac R, Marais T, Barkats M.

Mol Ther. 2013 Feb;21(2):282-90. doi: 10.1038/mt.2012.261. Epub 2013 Jan 8.


Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.

Ladroue C, Hoogewijs D, Gad S, Carcenac R, Storti F, Barrois M, Gimenez-Roqueplo AP, Leporrier M, Casadevall N, Hermine O, Kiladjian JJ, Baruchel A, Fakhoury F, Bressac-de Paillerets B, Feunteun J, Mazure N, Pouysségur J, Wenger RH, Richard S, Gardie B.

Haematologica. 2012 Jan;97(1):9-14. doi: 10.3324/haematol.2011.044644. Epub 2011 Sep 20.


Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.

Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P, Carcenac R, Astord S, Pereira de Moura A, Voit T, Barkats M.

Hum Mol Genet. 2011 Feb 15;20(4):681-93. doi: 10.1093/hmg/ddq514. Epub 2010 Nov 30.


PHD2 mutation and congenital erythrocytosis with paraganglioma.

Ladroue C, Carcenac R, Leporrier M, Gad S, Le Hello C, Galateau-Salle F, Feunteun J, Pouysségur J, Richard S, Gardie B.

N Engl J Med. 2008 Dec 18;359(25):2685-92. doi: 10.1056/NEJMoa0806277.

Supplemental Content

Loading ...
Support Center